Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2017
SIETES contiene 91906 citas

 
 
 1 a 20 de 434 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Trifirò G, de Ridder M, Sultana J, Oteri A, Rijnbeek P, Pecchioli S, Mazzaglia G, Bezemer I, Garbe E, Schink T, Poluzzi E, Froslev T, Molokhia M, Diemberger I, Sturkenboom M. Use of azithromycin and risk of ventricular arrhytmia. CMAJ 2017;189:E560-8. [Ref.ID 101536]
2.Enlace a cita original Cita con resumen
Sondergaard KB, Weeke P, Wissenberg M, Olsen A-MS, Fosbol EL, Lippert FK, Torp-Pedersen C, Gislason GH, Folke F. Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case–time–control study. Eur Heart J 2017;3:100-7. [Ref.ID 101478]
3.Enlace a cita original
Renoux C, Dell'Aniello S, Khairy P, Marras C, Bugden S, Turin TC, Blais L, Tamim H, Evans C, Steele R, Dormuth C, Ernst P, the Canadian Network for Observational Drug Effect Studies (CNODES) investigators. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. Br J Clin Pharmacol 2016;82:461-72. [Ref.ID 100688]
4. Cita con resumen
Anónimo. Métoclopramide, dompéridone: morts subites, arythmies ventriculaires. Prescrire 2016;36:351-4. [Ref.ID 100540]
5. Cita con resumen
Anónimo. Citalopram, escitalopram et allongements de l'intervalle QT. Prescrire 2016;36:348-51. [Ref.ID 100539]
6.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
7. Cita con resumen
Anónimo. Loperamide (Imodium): Drug Safety Communication - Serious heart problems with high doses from abuse and misuse. FDA U.S. Food and Drug Administration 2016:7 de junio. [Ref.ID 100377]
8. Cita con resumen
Rector TS, Adabag S, Cunningham F, Nelson D, Dieperink E. Outcomes of citalopram dosage risk mitigation in a veteran population . Am J Psychiatry 2016:10 de mayo. [Ref.ID 100319]
9. Cita con resumen
Eggleston W, Clark KH, Marraffa JM. Loperamide abuse associated with cardiac dysrhythmia and death. Ann Emerg Med 2016:26 de abril. [Ref.ID 100271]
10. Cita con resumen
Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ 2016;352:i1350. [Ref.ID 100143]
11.Enlace a cita original
Thomas SHL, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol 2016;81:420-7. [Ref.ID 100138]
12. Cita con resumen
Anónimo. QT interval and drug therapy. Drug Ther Bull 2016;54:33-6. [Ref.ID 100134]
13. Cita con resumen
Anónimo. Hydroxyzine (Atarax, Ucerax): risk of QT interval prolongation and torsade de pointes. Drug Safety Update 2015;8:1. [Ref.ID 99021]
14. Cita con resumen
Villamañán E, Armada E, Ruano M. Prolongación del intervalo QT inducido por fármacos: ¿conocemos sus riesgos?. Med Clin (Barc) 2015;144:269-74. [Ref.ID 98921]
15. Cita con resumen
Degner D. Severe adverse reactions associated with quetiapine. BMJ 2015;350:h1575. [Ref.ID 98872]
16. Cita con resumen
Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN, Canadian Drug Safety and Effectiveness Research Network.. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. Can Med Assoc J 2015;187:E138-143. [Ref.ID 98851]
17. Cita con resumen
Anónimo. Télithromycine: bilan des effets indésirables. Prescrire 2014;34:512-5. [Ref.ID 98075]
18. Cita con resumen
Anónimo. Sorafenib (Nexavar) for thyroid cancer. Med Lett Drugs Ther 2014;56:43-4. [Ref.ID 97918]
20.Enlace a cita original Cita con resumen
Voon V, Saiva L, O'Kelly S, Keane D. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis – insights into possible drug mechanism. Eur J Clin Pharmacol 2014;70:373-5. [Ref.ID 97280]
Seleccionar todas
 
 1 a 20 de 434 siguiente >>